The risks and burdens were higher in people who were hospitalized during the acute phase, and highest in those who needed ICU care during the acute phase.
But risks were evident even in those non-hospitalized (these people represent the majority of people with #COVID19).
People who were hospitalized and had acute kidney injury #AKI during the acute phase are at highest risk of poor kidney outcomes.
The risk was lower in people who did not have #AKI during the acute phase.
But again, risk was evident (and not trivial) among non-hospitalized.
Compared to non-infected controls, 30-day COVID-19 survivors exhibited excess eGFR decline of -3.26 (-3.58, -2.94), -5.20 (-6.24, -4.16), and -7.69 (-8.27, -7.12) mL/min/1.73m2/year in non-hospitalized, hospitalized, and those in ICU during the acute phase of COVID-19 infection.
Summary:
What happens to the kidneys in survivors of COVID-19?
Increased risks of:
- Acute kidney injury
- Decline in kidney function
- End-stage kidney disease
#Longcovid is a multifaceted disease; it can affect multiple organ systems including respiratory, cardiovascular, nervous, mental health, metabolic, gastrointestinal, kidneys, and other organ systems.
People with #longcovid have increased risk of incident use of several therapeutics including pain medications (opioids and non-opioids), antidepressants, anxiolytics, antihypertensives, and oral antihyperglycemics and evidence of laboratory abnormalities in multiple organ systems